Evaluating cardiac disorders associated with triazole antifungal agents based on the US Food and Drug Administration Adverse Event reporting system database
Introduction:Triazole antifungal agents are widely used to treat and prevent systemic mycoses. With wide clinical use, the number of reported adverse events has gradually increased. The aim of this study was to analyze the cardiac disorders associated with TAAs (fluconazole, voriconazole, itraconazo...
Main Authors: | Jinhua Chen, Shijun Xu, Weijiang Yu, Cuicui Sun, Wenzhou Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-03-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1255918/full |
Similar Items
-
Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
by: Jianxing Zhou, et al.
Published: (2022-12-01) -
Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database
by: Junwei Wang, et al.
Published: (2024-03-01) -
Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study
by: Yun Li, et al.
Published: (2024-03-01) -
Retrospective analysis of adverse events with spironolactone in females reported to the United States Food and Drug Administration
by: Yu Wang, BA, et al.
Published: (2020-09-01) -
Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2023-05-01)